The study describes the development and validation of a new microwell-based spectrophotometric assay for determination of olmesartan medoxomil (OLM) in tablets. The formation of a colored charge-transfer (CT) complex between OLM as an n-electron donor and 2,3-dichloro--5,6-dicyano-1,4-benzoquinone (DDQ) as a p-electron acceptor was investigated, and employed as the basis for the development of the new assay. The proposed assay was conducted in 96-microwell plates. The absorbance of the colored-CT complex was measured at 460 nm with a microplate reader. Optimum conditions of the reaction and the analytical procedures of the assay were established. Under the optimum conditions, a linear relationship with a good correlation coefficient was found between the absorbance and the concentration of OLM in the range of 2-200 µg per well. The limits of detection and quantitation were 0.53 and 1.61 µg per well, respectively. No interference was observed from the excipients present in OLM tablets or from hydrochlorothiazide and amlodipine besylate that were co-formulated with OLM in some of its formulations. The assay was successfully applied to the analysis of OLM in tablets with good accuracy and precision. The assay described herein has a great practical value in the routine analysis of OLM in quality control laboratories, since it has a high throughput property and consumes low volumes of organic solvent. It thus offers a reduction in the exposure of analysts to the toxic effects of organic solvents, as well as a reduction in the cost of analysis.
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Keywords: olmesartan medoxomil, spectrophotometry, charge-transfer complex, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, microwell assay Olmesartan medoxomil [OLM, (5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2--hydroxy-propan-2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate, Fig. 1 ], is the newest member of non-peptide angiotensin II receptor antagonists used worldwide in the treatment of hypertension. It is an ester prodrug, which is completely and rapidly hydrolyzed to the active acid form, olmesartan. OLM exerts its action mainly via a selective blockade action on AT1 receptors and the consequent reduced pressor effect of angiotensin II (1, 2) . OLM may be used alone or in combination with other antihypertensive agents (e.g., hydrochlorothiazide).
OLM has not yet been officially described in any pharmacopoeia. A literature survey revealed that several analytical methods were reported for its determination. These methods include high-performance thin-layer chromatography (3), liquid chromatography (3) (4) (5) (6) (7) (8) (9) , and capillary zone electrophoresis (10) . Also, a few spectrophotometric methods have been reported for the analysis of OLM in pharmaceutical tablets (11) (12) (13) . Unfortunately, these methods suffer from major drawbacks such as decreased selectivity due to measuring the native light absorption of OLM in the blue-shifted ultraviolet region, which might be subjected to interferences (11, 12) . Besides, the tedious liquid-liquid extraction procedures use large volumes of organic solvents in the methods based on the formation of ion-pair associates (13) . Therefore, the development of a new alternative spectrophotometric method for the determination of OLM in pharmaceutical formulations is essential.
The charge-transfer (CT) reaction between the electron-donating pharmaceuticals and electron-accepting reagents is widely employed as the basis for the development of visible spectrophotometric methods (14) (15) (16) . These facts promoted our interest in employing the CT-reaction as a basis for the development of a new spectrophotometric method for OLM determination. However, the CT-based spectrophotometric methods employing the conventional spectrophotometers are not automated and consequently their throughput is low; thus their applications in pharmaceutical quality control laboratories are limited. Moreover, these methods suffer from the consumption of large volumes of organic solvents, which leads to high analysis costs, and more importantly, the exposure of analysts to the toxic effects of organic solvents (17, 18) . The present study describes the investigation of the CT reaction of OLM, as an electron donor, with the p-electron acceptor 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to be used in the development of a new 96-microwell spectrophotometric assay for the determination of OLM in tablets. 
Chemicals and tablets

Preparation of standard and sample solutions
Stock standard solutions. Ten mg of OLM was accurately weighed into a 5-mL calibrated flask, dissolved in 2 mL methanol and completed to volume with the same solvent. This stock solution was diluted with methanol to obtain suitable concentrations lying in the linear range of the assay. The OLM solutions were found to be stable for at least two weeks when kept in a refrigerator.
Tablet solutions. -Twenty tablets were weighed and finely powdered. A quantity of powder equivalent to 20 mg of OLM was transferred into a 10-mL calibrated flask, dissolved in 4 mL methanol, swirled and sonicated for 5 min, completed to volume with methanol, shaken well for 15 min, and filtered. The first portion of the filtrate was rejected, and a measured volume of the filtrate was diluted quantitatively with methanol to yield suitable concentrations lying in the linear range of the assay.
General analytical procedure
Accurately measured aliquots (100 µL) of the standard or sample solution containing varying amounts of OLM (2-200 µg) were transferred into wells of 96-microwell assay plates. A hundred microliters of DDQ solution (8.8×10 -2 mol L -1 ) were added and the reaction was allowed to proceed at room temperature (25 ± 1°C) for 5 min. Absorbances of the resulting solutions were measured at 460 nm with the microplate reader. Blank wells were treated similarly except that 100 µL of methanol was used instead of that sample, and absorbances of the blank wells were subtracted from those of the other wells.
Determination of the molar ratio
Job's method of continuous variation was employed. Master equimolar solutions (2×10 -3 mol L -1 ) of each of OLM and DDQ were prepared. Series of 200 mL portions of the master solutions of OLM and DDQ were made up comprising different complementary ratios (0:10, 1:9,............ 9:1, 10:0, inclusive) in each well of the 96-microwell assay plate. The reaction was allowed to proceed at room temperature (25 ± 1°C) for 5 min. Absorbances were measured at 460 nm by the microwell-plate reader against blank wells. The measured absorbances were plotted as a function of the OLM mole fraction.
Molecular modeling for the CT complex of OLM with DDQ
Molecular modeling for the CT complex was performed using CS Chem3D Ultra, version 9 (Cambridge Soft Corporation, Cambridge, MA, USA) implemented with molecular orbital computations software (MOPAC) and molecular dynamics computations software (MM2).
Validation of analytical procedures
Linearity and sensitivity. -Under the optimal reaction conditions, the calibration curve for the analysis of OLM by the proposed assay was constructed by plotting absorbances as a function of the corresponding concentrations. The regression equation was derived using the least-squares method. The limits of detection (LOD) and quantitation (LOQ) were determined using the formula: LOD or LOQ = kSD a /b, where k = 3.3 for LOD and 10 for LOQ, SD a is the standard deviation of the intercept, and b is the slope.
Accuracy and precision. -Accuracy of the proposed assay was assessed by analytical recovery studies. Recovery was determined by the standard addition method. Known amounts of OLM were added to pre-determined OLM-containing tablets (labeled to contain 20 mg of OLM), and then determined by the proposed assay. The precision of the proposed assay was determined on samples of drug solutions at three concentration levels (5, 50 and 100 mg per well). Five replicates of each concentration level were analyzed as a batch in a single assay run for evaluating the within-assay precision and on three consecutive days for evaluating the between-assay precision.
Selectivity. -Interference from the congenital drugs that are co-formulated with OLM in some dosage forms was studied. The drugs were amlodipine besylate and hydrochlorothiazide. Potential interferences of these drugs were studied in a ratio normally present in their combined dosage forms, and recovery values were calculated.
Robustness and ruggedness. -Robustness was examined by evaluating the influence of small variations in assay variables on its analytical performance. In these experiments, one parameter was changed whereas the others were kept unchanged. Ruggedness was also tested by applying the proposed method to the OLM assay using the same operational conditions but using two different instruments (instrument 1 and 2) in two different laboratories and at different elapsed times. In each case, the percentage recovery was calculated. Instrument-1 was a microwell-plate absorbance reader (ELx 808, Bio-Tek Instruments Inc., USA) and instrument-2 was a microplate/cuvette reader (Spectramax M5, Molecular Devices, USA).
RESULTS AND DISCUSSION
Assay development and design
In this study, OLM was selected based on its therapeutic importance, clinical success, and the expected electron-donating ability. Previous studies involving CT reactions with polyhalo-/ polycyanoquinone electron p-acceptors revealed that DDQ is one of the most efficient reagents in terms of reactivity (19) . Furthermore, its CT reaction with electron-donating analytes is instantaneous (15, 16) . The 96-microwell design of the proposed assay was based on the previous success of Darwish et al. (20) in using this design for determination of some other pharmaceuticals.
Reaction and spectral characteristics
The interaction of OLM with DDQ was allowed to proceed at room temperature and the absorption spectrum of the produced chromogen was recorded. OLM gave red colored chromogen showing the absorption maximum at 460 nm (Fig. 2) . This band was attributed to the formation of the radical anion DDQ - (21) , which was probably formed by the dissociation of an original donor-acceptor (D-A) complex: vents (e.g., chloroform). Different polar solvents were tested to prepare the DDQ solution: methanol, ethanol, 1-propanol, 1-butanol, and acetonitrile. Methanol offered the highest sensitivity; it was therefore selected. The optimum reaction time was determined by monitoring color development in the microwells at room temperature (25 ± 1°C).
Optimization of experimental conditions
Complete color development was attained instantaneously; however, for higher precision readings, the reaction was allowed to proceed for 5 min. The developed color remained stable at room temperature for at least further 30 min. A summary for the optimum conditions is given in Table I .
Molar ratio, molecular modeling and site of interaction
Job's method of continuous variation was used for determining the molar ratio of OLM to DDQ. It was concluded from the obtained Job's plot that the OLM/DDQ ratio was 1:1. This indicated that only one sites of interaction was involved in the formation of the colored CT complex in spite of the presence of more than one possible electron--donating sites in OLM structure (e.g., OH of the hydroxypropane-2-yl group and nitrogen atoms of the tetrazole ring). To investigate the site of interaction and postulate the reaction mechanism, modeling was performed for the CT complex. OLM and DDQ were energy-minimized alone and together. It was found that electron densities in the OLM molecule, located on the oxygen atom of OH of the hydroxypropane-2-yl group, the oxygen atom of the ester linkage and nitrogen atoms of the tetrazole were comparable (-39428, -33456, and -33085). Also, during the energy-minimization dynamics, it was found that the DDQ molecule moved toward the tetrazole moiety of OLM to form the CT complex (Fig. 3) . These facts, taking the molar ratio in account, confirmed that only tetrazole was involved in the complex formation. The other anticipated centers are not likely to contribute to the CT reaction, probably due the steric hindrance effect of the OLM molecule (15) .
Validation of the proposed assay
Linearity and sensitivity. -Beer law plot (10-points) was linear in the range of 2-200 mg per well with the correlation coefficient R = 0.9974. The LOD and LOQ values were 0.53 and 1.61 mg per well, respectively. Analytical parameters of the proposed assay are given in Table II .
Accuracy and precision. -Accuracy, expressed as recovery, was assessed and the mean analytical recovery was calculated. It was found to be 96.9-102.5 % (Table III) indicating acceptable model accuracy of the proposed assay.
In assessing precision, the relative standard deviations (RSD) were 1.0-1.7 % (Table  II) proving good precision of the assay for routine application in quality control laboratories. This high level of precision was, among others, attributed to the accuracy of the volumes that were concomitantly dispensed in the microwells by multi-channel pipettes, and completeness of the reaction in a small volume (200 µL).
Selectivity. -The proposed assay has the advantage that the measurements are performed in the visible region, away from the UV-absorbing interfering substances that might be co-extracted from dosage forms containing OLM. Amlodipine besylate (22, 23) and hydrochlorothiazide (24, 25) are co-formulated with OLM in some dosage forms; their chemical structures are given in Fig. 1 . Potential interferences of these drugs were studied and it was found that they exhibited no interferences with OLM in the proposed assay. This is evidenced from obtained good recovery values (97.9-99.8 %, Table IV) .
Selectivity of the CT reaction for OLM was attributed to its basic character (high electron densities found on nitrogen atoms of the tetrazole moeity), which allows formation of CT rather than hydrochlorothiazide, which does not have sufficient basicity to achieve CT reaction. Although amlodipine has a basic character, it was co-formulated with OLM as besylate salt which did not show any ability for CT reaction with DDQ when tested by the proposed procedure under the proposed assay conditions. Recovery of OLM in the presence of amlodipine besylate was 98.2-100.1 %; however, it was 189.5 -192.8 % when amlodipine base was used. Further, no interference was observed from the excipients with the proposed assay, as indicated by good recovery values of 96.9-102.5 % (Table III) . The absence of interference from the excipients, even though they contained basic component(s) was attributed to the extraction of OLM tablets prior to the analysis with methanol in which the excipients do not dissolve. Robustness and ruggedness. -In evaluating the robustness, it was found that a small variation in one of the parameters did not significantly affect the procedures; recovery values were 97.2-100.5 % (Table V) . This indicated the reliability of the proposed assay during its routine application for the analysis of OLM. Ruggedness of the proposed method was evaluated as well and it was found that the variations lab-to-lab and day-to-day did not exceed 2 % (Table V) .
Analysis of OLM tablets
The commercially available OLM tablets (labeled to contain 20 mg OLM) were subjected to analysis by the proposed and reported methods (11) the latter being based on the direct measurement of native UV absorption of OLM. The obtained results were then statistically compared. The exact content of OLM was 19.88-20.56 mg per tablet (Table  VI) . Values for t and F were calculated and found to be lower than the tabulated ones, indicating that there was no significant difference between, the proposed and the reported assays, at 95 % confidence level, in terms of their accuracy and precision.
CONCLUSIONS
The present study describes the development and validation of a microwell spectrophotometric assay for the determination of OLM based on its CT reaction with DDQ reagent. The assay described herein offers the following advantages:
(i) Providing a high throughput analytical methodology that can facilitate the processing of a large number of samples in a relatively short time. This property was attributed to measuring the color signals in 96 wells in ca 30 seconds by the plate reader.
(ii) Reduction in the consumption of organic solvents, the exposure of the analyst to the toxic effects of organic solvent and reduction in the cost of analysis. 
